Last reviewed 2026-04-20 · How we verify

Indanal (CLIDANAC)

Phase 2 active Small molecule

Indanal (generic name: CLIDANAC) is a clidanac drug. It is currently in Phase 2 development.

Indanal works by inhibiting a specific enzyme or pathway to produce its therapeutic effect.

Indanal (CLIDANAC) is a small molecule drug in the clidanac class, but specific details about its target, FDA approval status, and approved indications are not available. As a clidanac, it is a type of medication that works by inhibiting a specific enzyme or pathway. The commercial status of Indanal is unclear, and it is unknown whether it is patented or available as a generic. Further research is needed to determine its safety profile and potential side effects. Overall, Indanal is a relatively unknown medication with limited information available.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CLIDANAC
Drug class	clidanac
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Think of it like a key fitting into a lock. Indanal is like the key that blocks the action of a specific enzyme, which is like the lock. This helps to restore balance to the body's natural processes and can help to treat certain conditions.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Indanal CI brief — competitive landscape report
Indanal updates RSS · CI watch RSS

Frequently asked questions about Indanal

What is Indanal?

Indanal (CLIDANAC) is a clidanac drug.

How does Indanal work?

Indanal works by inhibiting a specific enzyme or pathway to produce its therapeutic effect.

What is the generic name of Indanal?

CLIDANAC is the generic (nonproprietary) name of Indanal.

What drug class is Indanal in?

Indanal belongs to the clidanac class. See all clidanac drugs at /class/clidanac.

What development phase is Indanal in?

Indanal is in Phase 2.

Drug class: All clidanac drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing